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Abstract 
Curative treatment of intrahepatic cholangiocarcinoma (ICC) and hilar 
cholangiocarcinoma (Klatskin tumors) is limited to surgical resection or orthotopic 
liver transplantation. However, not all patients benefit from a surgical approach and 
suffer from early tumor recurrence. Response to chemotherapy is generally poor and 
until today, no targeted therapy could be established. Metastasis-associated in colon 
cancer 1 (MACC1) is a recently discovered regulator of the HGF/Met/MAPK pathway, 
which induces proliferation, migration and invasion in cell culture, and metastasis in 
mice. MACC1 expression shows a significant correlation with Met expression in colon 
cancer tissue and is highly prognostic for the occurrence of distant metastasis and 
survival in colon cancer patients.  
Thus, we aimed to measure the expression of MACC1, Met and HGF mRNA in 
microdissected tumor tissue and the corresponding normal liver tissue of 156 
patients with Klatskin tumors (n=76) and ICC (n=80) using real time quantitative RT-
PCR. We used immunohistochemical staining to validate the results. MACC1 
expression in tumor tissue of both tumor entities was significantly higher than in 
corresponding normal liver tissue (p<0.001). Klatskin tumor patients with a history of 
tumor recurrence had significantly higher MACC1 expression than those without 
tumor recurrence (p=0.005). Univariate und multivariate survival analysis showed 
that Klatskin tumor patients with high MACC1 had a significantly shorter overall and 
disease-free survival (p=0001 and p<0.001, respectively). The multivariate analysis 
confirmed MACC1 to be an independent factor for overall survival in Klatskin tumor 
patients (HR 2.777; CI: 1.389-5.555; p=0.004).  
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Conclusion: Our study identified MACC1 as a highly prognostic biomarker for overall 
survival and disease-free survival in Klatskin tumor patients. MACC1 expression 
could become an important diagnostic tool and might be a candidate for targeted 
therapy. 
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tumor recurrence and metastasis could be an essential tool to guide the treatment of 
patients with cholangiocarcinomas.  
A multitude of growth factors and their respective signaling pathways have been 
described to be up-regulated in cholangiocarcinomas. These include the IGF/IGFR, 
EGF/TGF/EGFR, VEGF/PDGF/VEGFR, Wnt/β-catenin, and the hepatocyte growth 
factor (HGF)–Met pathway (8,9).  The receptor tyrosine kinase Met is frequently 
overexpressed in cholangiocarcinomas, and Met expression has been linked to 
tumor differentiation and prognosis (10-13). However, the prognostic value of Met 
seems to differ between ICC and Klatskin tumors, and one study even showed a 
better patient outcome in case of Met overexpression in ICC (10,12). 
Recently, our group discovered a new regulator of the HGF/Met/MAPK pathway, 
called Metastasis-associated in colon cancer 1 (MACC1). MACC1 was identified by a 
genome-wide search for differentially expressed genes in human colon cancer tissue, 
metastases, and normal tissue (14). The MACC1 gene is located on human 
chromosome 7 (7p21.1), the same chromosome that contains the genes of Met  
(7q31.2) and HGF (7q21.1). MACC1 turned out to be a powerful biomarker for the 
prediction of metachronous distant metastasis as well as survival in colon cancer 
patients. Based on the expression level of MACC1 mRNA, the negative and positive 
prediction of distant metastasis was 80% and 74%, respectively (14). 
MACC1 mRNA expression in colon cancer tissue showed a significant correlation 
with Met mRNA expression. This was further investigated by in vitro studies, which 
revealed that MACC1 induces proliferation, migration and invasion in different colon 
carcinoma cell lines. Moreover, MACC1 promoted scattering in the presence of HGF. 
MEK inhibitors suppressed cell scattering, and vice versa, active MAPK promoted 
MACC1 expression. Furthermore, Met proofed to be a transcriptional target of 
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MACC1. Thus, MACC1 is a regulator of the HGF/Met/MAPK signaling pathway 
(14,15). This shows that MACC1 is not only a surrogate marker, but that it is causal 
for the development of distant metastasis, which makes it a highly interesting 
therapeutic target beyond its use as a prognostic biomarker (16). 
Here we aimed at determination of the expression levels of MACC1, Met, and HGF in 
tumor and peritumoral tissue of ICC and Klatskin tumors. We investigate the 
relationship between MACC1, Met and HGF expression, and analyzed the prognostic 
significance of MACC1, Met and HGF expression for patient overall survival (OS) and 
disease-free survival (DFS). To the best of our knowledge, we present the first study 
to measure the expression level of MACC1, Met and HGF mRNA quantitatively in 
microdissected cholangiocarcinomas utilizing quantitative real-time RT-PCR 
technique (qRT-PCR) and immunohistochemistry.   
Here we show for the first time, that MACC1 mRNA expression predicts OS and DFS 
in Klatskin tumor patients. This renders it highly interesting as a prognostic tool and 
makes it a potential therapeutic target for this type of tumor. 
 
Experimental procedures 
Human subjects  
We obtained tumor specimens of 156 patients undergoing surgery between 1998 and 
2003 with ICC (n=80) and Klatskin tumors (n=76) from the Department of General-, 
Visceral- and Transplantation Surgery, Charité Universitätsmedizin Berlin, Campus 
Virchow Klinikum, Berlin, Germany. Matching peritumoral liver tissue was available in 
all cases. In addition, we obtained normal bile duct tissue from 3 individuals 
undergoing surgery for benign liver tumors. All patients were treated by liver 
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resection. None of the patients received (neo-) adjuvant chemotherapy, and none of 
them had liver transplant. Patients with primary sclerosing cholangitis were not 
included in this study. The clinical, histopathological, and epidemiological data of the 
entire group of patients are reported in Supplementary Table 1. The follow-up period 
after surgery ranged from 0 days to 4007 days, with a median follow-up of 733 days. 
Collection of patient tissue and clinical data was approved by the local ethics 
committee (Charité Universitätsmedizin Berlin). 
 
Tumor samples 
Tissue specimens were collected during surgery, immediately snap frozen in liquid 
nitrogen and stored at -80°C. The investigators were blinded for patient metadata. 
 
Histology and sample preparation 
Serial sections were made of each tumor specimen for hematoxilin eosin (HE) 
staining, for microdissection with subsequent RNA isolation and for 
immunohistochemistry. Of each tumor sample, a section was HE stained following 
routine protocol. All HE stained sections were given to the Department of Pathology, 
Charité Universitätsmedizin Berlin, and were examined by a certified pathologist. 
Tumor diagnosis was confirmed and the respective tumor cell population on the slide 
was marked as a reference for microdissection. Samples with poor quality (e.g., 
necrosis) or samples lacking cancerous tissue were omitted from further analyses. 
With the exception of tumor diagnosis, the pathologist was blinded for all data, 
including tumor stage and patient outcome. 
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RNA extraction 
Tumor samples were microdissected and the material was directly immersed into 
lysis buffer. Total RNA extraction was performed with the GeneMATRIX Universal 
RNA Purification Kit (Roboklon GmbH, Germany) according to the manufacturer 
protocol. Total RNA quality was assessed with a Bioanalyzer (2100 Bioanalyzer, 
RNA Pico Chips, Agilent, CA, USA) and concentration was measured with a 
NanoDrop spectrophotometer. 
 
qRT-PCR 
qRT-PCR was performed using the LightCycler 480 system (Roche Diagnostics). For 
each sample, a total of 50 ng RNA template was subjected to reverse transcription 
(RT) (MuLV Reverse Transcriptase, Applied Biosystems), and all subsequent qPCR 
reactions were done with the same RT reaction. Each qPCR reaction was carried out 
in duplicate with 5 ng cDNA template in a total reaction volume of 10 µl. For MACC1, 
Met, and for the house keeping gene glucose-6-phosphate-dehydrogenase 
(G6PDH), specific hybridization probes were used (synthesis TIB MOLBIOL, Berlin, 
Germany, and LightCycler hG6PDH Housekeeping Gene Set, Roche Diagnostics) 
with LightCycler FastStart DNA Master Hyprobe master mix (Roche Diagnostics). 
Detection of HGF mRNA was done with SYBR GoTaq qPCR Master Mix (Promega 
Corporation, USA). The respective primers (synthesis BioTeZ, Berlin, Germany) and 
hybridization probes used are shown in Supplementary Table 2. 
Quantification was done with the standard curve method. Total RNA of 
cholangiocarcinoma cell line EGI-1 (for MACC1, Met, G6PDH) and of glioblastoma 
cell line HU 87 (for HGF) was diluted to generate a standard curve. For each point on 
the standard curve, a separate RT reaction with the respective amount of RNA 
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template was carried out. Additionally, a 50 ng RNA template of both cell lines was 
used as a calibrator, and the target gene expression was calculated as percentage of 
the respective calibrator sample. Standard curve and calibrator sample, as well as a 
no-template control were included in every qPCR run. 
 
Immunohistochemistry 
Immunohistologic staining for MACC1, Met and HGF was carried out for 20 
specimens of each tumor entity. The samples were chosen based on normalized 
MACC1 qRT-PCR expression levels, whereas the specimens with the 10 highest and 
10 lowest MACC1 expression levels were chosen. Fresh 5 µm cryosections were air 
dried for one hour at room temperature, fixed in 10 mM HEPES buffer containing 
0,04% glutaraldehyde and 1% glucose, incubated with 0,9% hydrogen peroxide for 
30 minutes, permeabilized with PBS containing 0,5% Triton X100 and 2,5% goat 
serum for 10 minutes, and treated with biotin blocking reagents (DAKO). After 
blocking with 5% goat serum for 45 minutes, the sections were incubated with the 
respective primary antibody at 4°C over night (please refer to Supplementary Table 3 
for antibodies and dilutions). The sections were incubated with a biotinylated 
secondary antibody for 30 minutes and treated with a streptavidine peroxidase 
conjugate for 30 minutes (Strept ABC Complex, DAKO). The slides were developed 
with DAB for 1 minute (Liquid DAB+ Substrate, DAKO) and counterstained with 
hematoxilin. Sections without primary antibody served as controls. 
The slides were examined with an Axioplan 2 microscope (Zeiss). Pictures of 
representative tumor areas were taken of each specimen at 200-fold magnification 
(Axiocam HRc camera, Zeiss). The same exposure and whitepoint setting was used 
for all slides. Pictures were evaluated using the Axovision 4.2 software (Zeiss) and a 
11 
 
semi-quantitative scoring system was applied. Tumor cells were classified to exhibit 
no staining (0), weak staining (1), intermediate staining (2), or strong staining (3). 
Analysis was carried out by two independent investigators who were blinded for the 
study protocol. 
 
Statistical methods 
Quantitative variables are expressed as medians. For comparison of groups, 
Kruskall-Wallis analysis on ranks and Mann-Whitney-U test were used. Inner group 
comparison was done using the Wilcoxon test.  
Main study outcomes were DFS and OS of the patients. DFS was defined as the 
length of time after the primary operation the patient survived without sign of local 
recurrence or metachronous metastasis. OS was defined as length of time after the 
primary operation until patient death. Patients surviving less than 30 days after 
surgery were excluded from survival analysis to adjust for possible effects on survival 
related to surgical complications. For each tumor entity, median survival time and 
95% confidence interval (CI) was calculated by Kaplan-Meier analysis. MACC1, Met, 
and HGF cut-off values were determined by Receiver-Operating-Characteristics 
curve analysis (ROC). ROC was carried out for every gene examined with the binary 
outcome variables for OS and DFS. The respective expression value yielding the 
highest Youden index was used as the cut-off value for univariate and multivariate 
survival analysis. 
For the univariate survival analysis, categorical variables were tested using the log-
rank test, and metric variables were tested with the Cox proportional hazard model. 
For the Cox proportional hazards model, the hazard ratio (HR) with 95% confidence 
interval was reported as an estimate of the risk of variable specific death. Variables 
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with p<0.1 in the univariate analysis were included in the multivariate analysis. The 
multivariate analysis was performed using the backward stepwise procedure for 
building a Cox proportional hazards model. Time-dependency was tested for every 
variable in the multivariate analysis and could be excluded. In all statistical tests, P < 
0.05 was considered statistically significant. Statistical analysis was performed using 
IBM SPSS Statistics Version 20 (IBM Software Group, USA). 
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Results 
 
MACC1 mRNA expression in Klatskin tumors and ICC is significantly higher 
than in corresponding normal liver tissue 
MACC1, Met, and HGF mRNA expression could be detected in all tissues examined 
by qRT-PCR. MACC1 expression was significantly higher in Klatskin tumors 
compared to corresponding normal liver tissue, with 9.94 vs. 1.06 MACC1 mRNA 
expression/% calibrator (p<0.001; Figure 1A). MACC1 was also significantly higher 
expressed in ICC compared to corresponding normal liver tissue, with 8.98 vs. 0.75 
MACC1 mRNA expression/% calibrator  (p<0.001; Figure 1B). Met mRNA expression 
in Klatskin tumors was significantly lower compared to normal liver tissue (1.86 vs. 
3.22 Met mRNA expression/% calibrator; p=0.002). Met mRNA expression in ICC did 
not differ significantly from the values measured in the corresponding normal liver 
tissue controls. HGF mRNA expression in all tumor tissues observed was 
significantly lower than in corresponding normal liver tissue: for Klatskin tumors 17.85 
vs. 160.63, and for ICC: 20.82 vs. 187.60 HGF mRNA expression/% calibrator; all 
p<0.001. 
The median expression level of MACC1 in biliary tumors was significantly higher than 
in the bile duct normal tissue controls, which showed MACC1, Met, and HGF mRNA 
expression levels comparable to normal liver tissue (Figure 1C).  
We further investigated the expression levels of MACC1, Met, and HGF in selected 
histopathological subgroups (tumor size pT, lymph node involvement pN, metastasis 
pM, tumor grading G, and UICC stage) of each tumor entity. In the Klatskin tumor 
cohort, MACC1 mRNA expression was significantly higher in patients with a tumor 
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size of pT3 and pT4 than with pT1 and pT2, with 4.14 (pT1+2) vs. 8.03 (pT3+4) 
MACC1 mRNA expression/% calibrator (p=0.012; Figure 2A). MACC1 mRNA 
expression did neither differ significantly between the different UICC stages (Figure 
2B), nor between the other major clinical features (pN, pM, and G). Met mRNA 
expression was also significantly higher in patients with a tumor size of pT3 and pT4 
(1.27 vs. 2.19 Met mRNA expression/% calibrator; p=0.002) (Figure 2C). 
No significant differences of Met mRNA expressions were found between the UICC 
stages and other histopathological categories in Klatskin tumor patients. For HGF 
mRNA expression, no significant differences could be detected for any of the 
analyzed parameters within the Klatskin tumor cohort. 
In the ICC group, MACC1, Met, and HGF mRNA expression did not differ 
significantly between the histopathologic subgroups with respect to pT, pN, pM, and 
G category as well as UICC stage. 
 
Survival analysis 
MACC1 mRNA expression is a significant and independent prognostic marker 
for OS in Klatskin tumor patients 
Next, we aimed to analyze the prognostic value of MACC1 expression in these tumor 
entities. ROC analysis was used to determine a cutoff value for OS and DFS. In total 
61 out of 76 patients in the Klatskin tumor cohort survived more than 30 days after 
surgery and had complete clinical follow up. They were considered for survival 
analysis. In this group, ROC analysis for OS and DFS both yielded a significant area 
under the curve (AUC) for MACC1 mRNA expression (Figure 3A). Thus, the Klatskin 
tumor cohort was divided in group low and high MACC1 mRNA expression according 
to the cutoff value calculated by Youden index, which is 8.96 MACC1 mRNA 
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expression/% calibrator (sensitivity 70.8%; specificity 72%) (Figure 3A). 
Epidemiological, clinical, and histopathological data of Klatskin tumor patients 
grouped according to MACC1 mRNA expression status are reported in Table 3. 
 
Univariate survival analysis 
The median OS time in the Klatskin tumor cohort was 768 days (CI: 255-1251 days). 
Patients with high MACC1 expression had a median OS time of 613 days (CI: 300-
926), which was significantly shorter than patients with low MACC1 expression 
(median survival time: 2257 days; CI: n/a; p=0.001) (Figure 3B). Survival analysis 
was repeated using the COX regression model with MACC1 as a binary as well as 
continuous variable. Both regression models confirmed the results of the log rank 
test. With MACC1 as continuous variable, the HR was 1.047 (CI: 1.024-1.072; 
p<0.001).  
For Met mRNA expression, ROC analysis did not show a significant AUC. Using the 
median as cutoff value, univariate analysis showed Met mRNA expression to have a 
significant influence on OS. In cases with high Met mRNA expression, median 
survival time was reduced to 199 days (CI: 25-803 days), while patients with low Met 
mRNA expression had a median survival time of 340 days (CI: 588-1920 days; 
p=0.041). However, the effect of Met mRNA expression on OS was markedly weaker 
than for MACC1 mRNA expression. HGF mRNA expression had no significant 
influence on survival when analyzed with the log rank test. Using the COX regression 
model, Met and HGF mRNA expression had no significant effect on OS and DFS. 
Another variable with significant influence on OS in the univariate analysis was the 
lymph node status with 1505 days for pN0 (CI: 870-2140 days) and 418 days for pN1 
(CI: 224-612 days; p=0.011). Tumor size pT (p=0.07), occurrence of metastasis M 
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(p=0.209), tumor differentiation G (p=0.368), and resection margin R (p=0.169) were 
not significant parameters in our study. Patient age at surgery (p=0.545) and gender 
(p=0.950) had no significant effect on OS in the Klatskin tumor cohort.  
 
Multivariate analysis for survival  
We conducted a multivariate analysis to evaluate whether MACC1 mRNA expression 
is an independent factor for OS in the Klatskin tumor cohort. We used the COX 
regression model with the stepwise backwards procedure with all variables that had a 
significance of p<0.1 in the univariate analysis. Independent prognostic significance 
was detected for MACC1 expression with the ROC derived cutoff (HR 2.777; CI: 
1.389-5.555; p=0.004) and lymph node status pN (HR 2.114; CI: 1.114-4.015; 
p=0.022). Met expression (p=0.601) and tumor size pT (p=0.296) were not 
significant. Therefore, we found MACC1 mRNA expression to be a strong and 
independent predictor of OS in Klatskin tumor patients. 
 
MACC1 mRNA expression is a significant prognostic marker for DFS in 
Klatskin tumor patients 
Patients with a history of tumor recurrence had significantly higher MACC1 mRNA 
expression than patients without tumor recurrence (Figure 4A). Moreover, patients 
with high MACC1 expression had a significantly shorter median DFS (753 days; CI: 
341-1165 days) than patients with low MACC1 expression (>3119 days; CI: n/a; 
p<0.001) (Figure 4B). Met expression and HGF expression did not significantly 
influence DFS. 
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MACC1 mRNA expression is not a prognostic marker for survival of ICC 
patients 
In the ICC group, 72 out of 80 patients were eligible for survival analysis. We were 
not able to generate a significant AUC for MACC1 mRNA expression with ROC 
analysis for ICC. In ICC, the AUC was 0.263, hence we did not use a ROC-derived 
cutoff value for survival analysis. Median survival time in the entire ICC group was 
566 days (CI: 420–711 days). Using the median expression value (8.98 MACC1 
mRNA expression/% calibrator) as cutoff, log rank test showed a significantly better 
survival in ICC patients with high MACC1 expression (median survival time: 1021 
days; CI: 447–1595 days) than in patients with low MACC1 expression (median 
survival time: 437 days; CI: 293–581 days; p=0.002). Met (p=0.864) and HGF 
(p=0.295) expression showed no significant effect on OS when employing the 
median expression value as cutoff. 
The univariate analysis for ICC showed a significant effect on OS time for tumor size 
pT (pT1+2: 1172 days; CI: 516–1828 days; pT 3+4: 440 days; CI: 310–570 days; 
p=0.006), and lymph node status pN (pN0: 881 days; CI: 327-1435 days; pN1: 357 
days; CI: 296–418 days; p=0.006). Patient age at surgery (p=0.068), gender 
(p=0.216), metastasis M (p=0.237), tumor grading G (p=0.164), and resection margin 
R (p=0.415) were not significant variables for the prediction of OS time in the ICC 
group. 
 
Correlation of MACC1 mRNA expression and Met mRNA expression 
To further investigate the interrelationship between MACC1 and Met, we performed 
linear regression analysis for mRNA expression values in normal liver tissue and in 
tumor tissue on log transformed expression values. In Klatskin tumor tissue, there 
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was a strong correlation between MACC1 mRNA expression and Met mRNA 
expression (R=0.663, R2=0.440, p<0.001). In contrast, there was no significant 
correlation of MACC1 and Met mRNA expression in normal liver tissue (R=0.225, 
R2=0.051, p=0.056). In ICC tumor tissue, no correlation of MACC1 and Met mRNA 
expression could be detected.  
 
Correlation of HGF mRNA expression and Met mRNA expression 
Because HGF is the ligand for the Met receptor, we speculated that HGF and Met 
mRNA expression values might correlate better in normal liver tissue than in tumor 
tissue. For all tumor entities observed, we found a markedly higher correlation of 
HGF and Met mRNA expression in normal liver tissue than in tumor tissue using the 
linear regression model on log transformed expression values: Klatskin tumor tissue 
and normal liver tissue: R=0.325 vs. R=0.558, respectively; ICC tumor tissue and 
normal liver tissue: R=0.209 vs. R=0.719, respectively. 
 
Validation of results obtained by qRT-PCR with immunohistochemistry 
To validate the results obtained by qRT-PCR on the protein level, tissue samples 
were stained for MACC1, Met, and HGF. The results of semi-quantitative scoring of 
the staining intensity were plotted against the quantitative expression values 
measured by qRT-PCR. Spearman’s rank correlation analysis showed a significant 
correlation between the results of qRT-PCR and immunohistochemistry (Figure 5). In 
all tissue specimens, staining for MACC1 was visible in the cytoplasm with some cell 
membrane staining, which was also the case for staining of Met. HGF staining was 
only visible in the cytoplasm. Representative pictures of immunohistochemistry are 
shown in Figure 6. 
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Discussion 
In summary, here we report a first study measuring the expression for MACC1 
mRNA, Met mRNA, and HGF mRNA quantitatively in microdissected 
cholangiocarcinomas. In our study, qRT-PCR was a suitable method to determine 
MACC1 expression in frozen tumor tissue. Most importantly, we identified MACC1 as 
a significant and independent prognostic biomarker for OS and DFS in Klatskin tumor 
patients. 
The main goal of our study was to investigate whether MACC1 is of prognostic value 
in patients with ICC and Klatskin tumors. Additionally, we wanted to investigate the 
interrelationship between MACC1, Met, and HGF mRNA expression in these tumors 
and compare the prognostic usefulness between these genes. The scientific basis for 
this project was a study performed by our group, which identified MACC1 as a key 
regulator of the HGF-Met signaling pathway and demonstrated its ability to predict 
colon cancer metastasis not only when measured in solid tumors, but also when 
detected in human plasma (14,17). Therefore, we determined MACC1, Met, and 
HGF mRNA expression levels quantitatively using real-time RT-PCR in micro-
dissected tumor tissue. 
We found highly elevated MACC1 mRNA expression values in intrahepatic and hilar 
cholangiocarcinoma. MACC1 mRNA expression was approximately 10 times higher 
in intrahepatic cholangiocarcinoma and Klatskin tumors than in peritumorous normal 
liver tissue. Gene expression profliling in ICCs also showed elevated MACC1 
expression levels (18). While the MACC1 expression in the Klatskin tumor cohort did 
not differ between the UICC tumor stages, we found significantly higher MACC1 
expression values in patients with a tumor size of pT3 and pT4 compared to pT1 and 
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pT2. In addition, patients with a history of tumor recurrence had a significantly higher 
MACC1 expression than those without tumor recurrence. Although all Klatskin tumor 
patients with a poorly differentiated tumor (G3) were found in the high MACC1 mRNA 
expression group (Table 3), we found no significant difference in MACC1 mRNA 
expression between the different tumor grading categories. This finding is somewhat 
similar to the results reported on MACC1 expression in colorectal carcinoma, where 
MACC1 expression did not differ significantly between the different UICC stages but 
was significantly higher expressed in patients with metachronous metastasis (14,19).   
Performing survival analysis, we found patients with low MACC1 expression having a 
highly significantly longer DFS time and a significantly longer OS time. To the best of 
our knowledge, this is the first report of a prognostic biomarker for Klatskin tumor 
patients.  
It might seem controversial that, given the fact that MACC1 expression was elevated 
in ICC and Klatskin tumors alike, high MACC1 expression correlated only in the 
Klatskin tumor group with a poorer patient outcome. While both intrahepatic ICC and 
Klatskin tumors are neoplasms of the biliary system, they are clinically treated as 
different entities and show a different clinical behavior (20). This could be explained 
embryologically: Intrahepatic small bile ducts, which give rise to ICC, derive from 
hepatic progenitor cells. Klatskin tumors originate from the extrahepatic bile duct, 
which derives from the posterior ventral foregut together with the ventral pancreas 
(21). Furthermore, the signaling pathways active in these tumors are not the same, 
as was demonstrated by Mijamoto et al., who found e.g. different expression levels of 
Met in intrahepatic and extrahepatic cholangiocarcinoma (10).  
Met mRNA expression in Klatskin tumors was also of prognostic significance, 
although it was a markedly weaker biomarker and had no statistical significance in 
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ROC analysis. In Klatskin tumor tissue, we found a high correlation between MACC1 
and Met mRNA expression. A significant correlation of MACC1 and Met expression 
has been reported for colorectal carcinoma, gastric carcinoma, and hepatocellular 
carcinoma (14,22-25). As MACC1 is a transcriptional regulator of Met, this suggests 
that MACC1 plays a pivotal role in carcinogenesis in Klatskin tumors. In ICC, no 
significant correlation between these genes was found. Furthermore, we found a 
significant correlation of HGF and Met expression in normal liver tissue. However, 
this correlation was lost in Klatskin tumor tissue, which might indicate that HGF as 
the ligand of Met is not the activator of the HGF-Met signaling pathway in these 
tumors. This is in accordance with studies in other tumor entities, which show a 
decline in HGF expression in case of Met being overexpressed (26). 
Currently, the only curative therapeutic option available for Klatskin tumors is radical 
surgery with complete tumor removal (27-29). However, surgical resectability is often 
not given, and liver transplantation might seem a rational therapeutic approach to 
achieve complete tumor removal. Interestingly, in our patient cohort the only 
independent prognostic marker besides MACC1 expression was the lymph node 
status, which was also of prognostic significance in transplant trials for Klatskin 
tumors (7,30,31) The possibility of tumor recurrence is the major drawback for liver 
transplantation, and given the lack of biomarkers for the prediction of tumor 
recurrence, acceptable results for liver transplantation in Klatskin tumor patients are 
only feasible with a strict regime of preoperative staging and neoadjuvant 
chemoradiation (32,33). Consequently, liver transplantation for Klatskin tumors is 
only carried out in the setting of clinical studies. MACC1 could be a useful biomarker 
to identify a group of Klatskin tumor patients with a favourable clinical outcome after 
liver resection or liver transplantation. 
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Beyond its use as a biomarker, MACC1 is a promising candidate for targeted 
therapy. In vitro experiments targeting MACC1 with small hairpin RNA showed 
reduced tumor cell migration and invasion in colorectal, ovarian and hepatocellular 
carcinoma and in vivo experiments showed a reduction of tumor growth and 
metastasis formation in SW620 cell xenografts in mice by using MACC1 shRNA 
(14,34-36). The development of a selective inhibitor, for instance a small molecule 
targeting the MACC1 protein is a promising treatment modality for the prevention of 
tumor growth and tumor metastasis. This could be a potential adjuvant treatment for 
Klatskin tumor patients to reduce the risk of tumor recurrence. 
 
Conclusion 
In summary, our study identifies MACC1 as a highly prognostic biomarker for OS and 
DFS in Klatskin tumor patients. Prospective validation of MACC1 mRNA expression 
in Klatskin tumors may eventually make it a tool in clinical decision making to allocate 
patients suitable for curative surgery, which includes liver transplantation. 
Furthermore, down regulation of MACC1 might be an interesting therapeutic strategy 
to halt tumor progression.  
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Figure legends 
 
Figure 1 
MACC1 mRNA expression in Klatskin tumors (A) and intrahepatic 
cholangiocarcinoma (B) with corresponding peritumorous normal liver tissue, and 
normal bile duct tissue (C), determined by qRT-PCR. Wilcoxon signed-rank test. 
 
Figure 2 
(A) MACC1 mRNA expression in Klatskin tumors with a size of pT1 or pT2 (median 
4.14; n=16) and pT3 or pT4 (median 8.03; n=54), measured by qRT-PCR. (B) 
MACC1 mRNA expression in Klatskin tumor tissue of UICC stages I+II (n=63) and 
stages III+IV (n=5) as determined by qRT-PCR. (C) MET mRNA expression in 
Klatskin tumors with a size of pT1 or pT2 (median 1.27; n=16) and pT3 or pT4 
(median 2.19; n=54), as determined by qRT-PCR. All Mann Whitney U Test. 
 
Figure 3 
(A) Receiver operator curve (ROC) for MACC1 mRNA expression with patient death 
as binary outcome variable in the Klatskin tumor group. AUC: Area under the curve. 
n=61. (B) Kaplan Meier analysis for OS of the entire Klatskin tumor cohort based on 
MACC1 mRNA expression level with ROC-derived cutoff value. Log rank test. 
 
  
Figure 4 
(A) MACC1 mRNA expression in Klatskin tumors from patients without tumor 
recurrence (median 5.25; n=50) and with tumor recurrence (median 14.77; n=24). 
Mann Whitney U Test. (B) Kaplan Meier analysis for DFS of the entire Klatskin tumor 
cohort based on MACC1 mRNA expression level with ROC-derived cutoff value. Log 
rank test. 
 
Figure 5 
Scatter graph: Semi-quantitative intensity score of immunhistochemical staining (no 
staining 0, weak staining 1, intermediate staining 2, or strong staining 3) for MACC1 
and MACC1 mRNA expression measured by qRT-PCR in corresponding tissue 
samples of Klatskin tumor and ICC. Significant correlation was found with a Pearson 
and Spearman’s rank correlation coefficient of R = 0,406 (p = 0,05) and R = 0,416 (p 
= 0,048), respectively.  
 
Figure 6 
Representative pictures of immunohistochemical staining for MACC1 in Klatskin 
tumor tissue. Staining intensity was classified as no staining (A), weak staining (B), 
intermediate staining (C), and strong staining (E). Immunohistochemical staining was 
done using the ABC method, counterstaining with hematoxilin. 200-fold 
magnification. 
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Table 1 Clinical features of the Klatskin Series (n=61) according to ROC based MACC1 grouping considered for 
survival analysis. 
   MACC1  
Clinical features   Total number of Cases low (n=26) high (n=35) P † 
Status     <0,001 
 alive  18 14 (53.8) 4 (11.4)  
 dead  43 12 (46.2) 31 (88.6)  
Gender     0,395 
 male 40 14 (53.8) 15 (42.9)  
 female 36 12 (46.2) 20 (57.1)  
Age  61 60±10 60±10 0,830 
Size     0,744 
 pT1 2 1 (3.85) 1 (3.03)  
 pT2 11 6 (23.07) 5 (15.15)  
 pT3 43 18 (69.23) 25 (75.75)  
 pT4 3 1 (3.85) 2 (6.07)  
Node Involvement     0,239 
 pN0 33 17 (65.4) 16 (50)  
 pN1 25 9 (34.6) 16 (50)  
Metastasis     0,202 
 pM0 57 26 (100) 31 (93.3)  
 pM1 2 0 (0) 2 (6.7)  
Histological Grade     0,039 
 G1 2 1 (5.6) 1 (3.7)  
 G2 35 17 (94.4) 18 (66.7)  
 G3 8 0 (0) 8 (29.6)  
Resection Margin     0,806 
 R0 38 17 (94.4) 21 (67.7)  
 R1 17 7 (5.6) 10 (32.3)  
 
Table values are given as mean ± SD for continuous variables and n (%) for categorical variables. † P 
value is for t test (continuous variable) or χ² test (categorical variables). 
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 Supplementary Table 1 Clinical features of the entire study Series (n=156) according to MACC1 grouping. 
   MACC1  
Clinical features   Total number of Cases low (n=73) high (n=81) P † 
Status     0,501 
 alive  31 16 (23,5) 15 (19,0)  
 dead  116 52 (76,5) 64 (81,0)  
Gender     0,132 
 male 72 39 (53,4) 33 (41,3)  
 female 81 34 (46,6) 47 (58,7)  
Age  156 60±10 61±10 0,648 
Size     0,454 
 pT1 14 6 (8,6) 8 (10,8)  
 pT2 24 15 (21,4) 9 (12,2)  
 pT3 95 43 (61,4) 52 (70,3)  
 pT4 11 6 (8,6) 5 (6,8)  
Node Involvement     0,178 
 pN0 72 36 (52,2) 36 (48,6)  
 pN1 71 33 (47,8) 38 (50,4)  
Metastasis     0,654 
 pM0 136 65 (92,9) 71 (95,9)  
 pM1 8 5 (7,1) 3 (4,1)  
Histological Grade     0,770 
 G1 2 1 (1,7) 1 (1,5)  
 G2 88 44 (74,6) 44 (67,7)  
 G3 34 14 (23,7) 20 (30,8)  
Resection Margin     0,899 
 R0 72 34 (54,0) 38 (55,1)  
 R1 60 29 (46,0) 31 (44,9)  
 
Table values are given as mean ± SD for continuous variables and n (%) for categorical variables. † P 
value is for t test (continuous variable) or χ² test (categorical variables). 
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Supplementary Table 2 Primers and probes for quantitative real time PCR 
Gene  Sequence 
MACC1 Forward primer TTC TTT TGA TTC CTC CGG TGA 
 Reverse primer ACT CTG ATG GGC ATG TGC TG 
 FITC probe GCA GAC TTC CTC AAG AAA TTC 
TGG AAG ATC TA 
 Red640 probe AGT GTT TCA GAA CTT CTG GAC 
ATT TTA GAC GA 
Met Forward primer GAG AAG CCC AAG CCC ATC C 
 Reverse primer GCC CAG GGC TCA GAG CTT 
 FITC probe GCA GAC GAG CTG ATG AAG AGA 
GTG GGT TTC 
 Red640 probe AGT ATG AGG GCA CCT ACA AGT 
GGG TGA ACC 
HGF Forward primer GGA CAA GAA CAT GGA AGA CT 
 Reverse primer ACA ACG AGA AAT AGG GCA AT 
G6PDH LightCycler hG6PDH Housekeeping Gene Set (Cat. No. 
03261883001, Roche Diagnostics) 
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 Supplementary Table 3 Antibodies for immunohistochemistry 
Antibody Dilution 
MACC1 (HPA020081, SIGMA) 1:250, 4°C over night 
Met (sc-10, Santa Cruz Biotechnology) 1:400, 4°C over night 
HGF (H-145) (sc-7949, Santa Cruz Biotechnology) 1:100, 4°C over night 
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